Brought to you by 
Enobia Pharma brings in $15mm of potential $47mm via Series D; round reaches $40mm
25 Feb 2021
Executive Summary
In what appears to be its fourth financing round, Enobia Pharma Inc. (developing drugs for genetic bone disorders for which there are no available treatments) raised $15mm from seven undisclosed investors. According to the Form D filing, the company could raise up to $47mm in three tranches. Enobia’s last fund-raise was an August 2009 Series C that generated $50mm; that money was expected to last through mid-2011.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Enobia Pharma brings in $15mm of potential $47mm via Series D; round reaches $40mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice